Oncology & Cancer

Gilteritinib superior in relapsed, refractory FLT3-mutated AML

(HealthDay)—For relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3), treatment with a selective FLT3 inhibitor, gilteritinib, results in significantly longer ...

Oncology & Cancer

High response seen for chemo in seniors with high-risk AML

(HealthDay)—A substantial proportion of older patients with high-risk acute myeloid leukemia (AML) treated with chemotherapy are long-term survivors, according to research published online June 7 in Cancer Medicine.

page 8 from 11